The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP)

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 35-40

  Nozawa, Motohiro ^a   Ohnuma, Tohru ^a,b   Matsubara, Yoichiro ^a   Sakai, Yoshie ^a   Hatano, Tokiko ^a   Hanzawa, Ryo ^a   Shibata, Nobuto ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Juntendo University Hospital   (Japan)

Author keywords

Olanzapine; Plasma concentration; Polymorphisms; Schizophrenia; Smoking

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; GENOMIC DNA; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; OLANZAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SEX FACTORS; SMOKING;

EID: 38549163810     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31816336fd     Document Type: Article

References (31)

1. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23:119-127.
2. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005;20:55-60.
3. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol. 1997;17:472-477.
4. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14-20.
5. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:250-254.
6. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology. 2003;170:157-166.
7. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens: when does therapeutic become toxic? J Forensic Sci. 2000;45:418-421.
8. Weizberg M, Su M, Mazzola JL, et al. Altered mental status from olanzapine overdose treated with physostigmine. Clin Toxicol. 2006;44:319-325.
9. Fellows L, Ahmad F, Castle DJ, et al. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit. 2003;25:682-689.
10. Aguglia E, De Vanna M, Onor ML, et al. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1229-1233.
11. Lu Z, Hu J, Chen CK, et al. Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:32-40.
12. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patientswith schizophrenia. Int J Geriatr Psychiatry. 2003;18:432-440.
13. Wang X, Savage R, Borisov A, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res. 2006;40:669-676.
14. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
15. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518-526.
16. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:570-574.
17. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit. 2002;24:512-517.
18. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and bio-transformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81-93.
19. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol. 1996;41:181-186.
20. Mori A, Maruo Y, Iwai M, et al. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos. 2005;33:672-675.
21. Saeki M, Saito Y, Jinno H, et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet. 2005;20:144-151.
22. Han XM, Ou-Yang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics. 2001;11:429-435.
23. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445-449.
24. Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics. 1993;3:256-263.
25. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995;5:215-223.
26. Overall JE, Gorman DR. The Brief Psychiatry Rating Scale. Psychol Rep. 1962;10:799-812.
27. Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1995;668:85-90.
28. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 2005;5:60-69.
29. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308-311.
30. Takata K, Saruwatari J, Nakada N, et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol. 2006;62:23-28.
31. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50:31-34.